Cui Xiaotian, Zhao Jinzhao, Zhou Xinda, Hua Ang, Chengxi, Tan Chen, and Han Wei Liu Ping, a 25-year-old living in Beijing, is queuing up outside the obesity clinic of the Peking University People’s Hospital early one morning, seeking a doctor’s prescription for the so-called “skinny jab” — a weight loss drug that has created a buying frenzy in China, where half the adults out of a total population of 1.4 billion are either overweight or obese.
Related Posts
syngene: Syngene gets booster dose of sky-high valuation, but investors cautiously upbeat on stock
Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over…
MSD: As MSD puts iconic Januvia and Janumet up for sale, India’s diabetes-drugs market goes into churn
A sharp surge in the number of diabetes patients, 77 million and counting, has turned India into a hotspot for…
How a 2012 bet supercharged Sun Pharma
Shares of Sun Pharmaceuticals, India’s largest drug manufacturer, gained more than 50% over the last one year. In its latest…
